Article

The 340B Drug Discount Program Needs Protection, Health Systems Urge Congress

While there's been controversy around the drug discount program for some time, the Health Resources and Services Administration plans to release a "mega-guidance" that will address several aspects of the 340B program.

Leaders of hospital and health systems across the country have urged members of Congress to protect the 340B drug discount program that is a backbone for hospitals that serve low-income Medicare and Medicaid patients. Additionally, the American Hospital Administration has expressed concerns about certain provisions within the 21st Century Cures Act, released by the House Energy and Commerce Committee.

Read the article on H&HN: http://bit.ly/1Hi4ZhU

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Interview with Miriam Freimer, MD, The Ohio State University Wexner Medical Center
Merrill H. Stewart, MD
Rachel Rohaidy, MD
Mansi Shah, MD
Mansi Shah, MD
CK Wang, MD, COTA
Gordon Crofoot, MD, PA
Merrill H. Stewart, MD
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Hamlet Gasoyan, PhD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo